Camden Biotechnology began operations in September 2018 The

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April.

2018

On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $14,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees.

On October 1, borrowed $11 million cash from Second Commercial Bank under the line of credit and issued a five-month promissory note. Interest at the prime rate of 9% was payable at maturity. Management planned to issue 10-year bonds in February to repay the note.

Received $2,300 of refundable deposits in December for reusable containers used to transport and store chemical-based products.

For the September–December period, sales on account totaled $4,560,000. The state sales tax rate is 3% and the local sales tax rate is 3%. (This is a summary journal entry for the many individual sales transactions for the period.)

Recorded the adjusting entry for accrued interest.


2019

In February, issued $9.5 million of 10-year bonds at face value and paid the bank loan on the March 1 due date.

Half of the storage containers covered by refundable deposits were returned in March. The remaining containers are expected to be returned during the next six months.


Required:
1. Prepare the appropriate journal entries for 2018 and 2019 transactions.
2. Prepare the current and long-term liability sections of the December 31, 2018, balance sheet. Trade accounts payable on that date were $312,000.
  

Solution

Ans:-

Journal Entries :-

Sales Taxes Payable A/c [(3% + 3%) ×

$4,560,000]

Balance sheet

December 31, 2018

Current Liabilities :

SL.No Particulars Debit Credit
Year : 2018
a. No Journal entry is required
No Journal entry is required
No entry is required because the money has not yet been borrowed
b. Cash A/c $11,000,000
Notes Payable A/c $11,000,000
(5 - month, 9% note, dated - October 1)
c. Cash A/c $2,300
Liability - Refundable Deposits A/c $2,300
d. Accounts Receivable A/c * $4,833,600
Sales Revenue A/c $4,560,000

Sales Taxes Payable A/c [(3% + 3%) ×

$4,560,000]

$273,600
* [4,360,000 + (3% + 3%) × $4,360,000]
e. Interest Expense A/c $95000000
Interest Payable A/c $95000000
Year : 2019
f. Cash A/c $95000000
Bonds Payable A/c $95000000
Interest Expense A/c (10% × $11,000,000 × 2/12) $183333
Interest Payable A/c $275,000
Notes Payable A/c $11,000,000
Cash A/c $11,458,333
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through Mar
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through Mar

Get Help Now

Submit a Take Down Notice

Tutor
Tutor: Dr Jack
Most rated tutor on our site